financetom
Business
financetom
/
Business
/
Ecopetrol's Reficar wins court judgment in long-running dispute with McDermott
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ecopetrol's Reficar wins court judgment in long-running dispute with McDermott
Mar 21, 2024 8:18 PM
Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
Sep 8, 2025
Sept 8 (Reuters) - STRATHCONA RESOURCES ( STHRF ): * STRATHCONA RESOURCES ( STHRF ) - MEG BOARD DEAL IS UNFAIR TO MEG SHAREHOLDERS AND RESULT OF A BROKEN SALE PROCESS * STRATHCONA RESOURCES LTD. ( STHRF ) ANNOUNCES AMENDED AND EXTENDED OFFER TO ACQUIRE MEG ENERGY CORP. * STRATHCONA RESOURCES LTD ( STHRF ) - AMENDED OFFER EQUATES TO...
Chevron seeks diversified approach to refinery investment
Chevron seeks diversified approach to refinery investment
Sep 8, 2025
SINGAPORE, Sept 8 (Reuters) - Chevron ( CVX ) is looking to have a balanced portfolio of refineries, Brant Fish, the U.S. major's president, international products, said at the APPEC event in Singapore. There'll be places like Korea where we go investment heavy in petrochemicals and in heavy oil upgrading, Fish said of the firm's existing investments. And then there'll...
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
Sep 8, 2025
04:27 AM EDT, 09/08/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that results from a phase 3 trial of Tagrisso plus pemetrexed and platinum-based chemotherapy showed statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival compared with Tagrisso alone in patients with non-small cell lung cancer. The Tagrisso combination therapy showed a median...
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study
Sep 8, 2025
04:03 AM EDT, 09/08/2025 (MT Newswires) -- Alkermes ( ALKS ) said Sunday that a phase 2 study of its investigational drug alixorexton in patients with type 1 narcolepsy showed clinically meaningful and statistically significant improvements in wakefulness, cognition and fatigue that were sustained over a six-week treatment period. The 92-patient study met its primary endpoint of improvements in mean...
Copyright 2023-2025 - www.financetom.com All Rights Reserved